<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01365598</url>
  </required_header>
  <id_info>
    <org_study_id>PQPF912</org_study_id>
    <nct_id>NCT01365598</nct_id>
  </id_info>
  <brief_title>Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of Primaquine for Clearance of Gametocytes in Uncomplicated Falciparum Malaria in Uganda</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of lower doses of primaquine
      compared to the dose recommended by the WHO for reducing P. falciparum gametocytes in the
      infected human host to prevent transmission of falciparum malaria to the anopheles mosquito
      vector.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single dose of 0.75mg/kg primaquine base is recommended by the WHO to block transmission of
      falciparum malaria from infected humans to mosquitoes by clearing gametocytes. However, the
      optimal dose for safety and efficacy has not been evaluated. Dose-finding data is important
      because primaquine has a dose-dependent risk of causing haemolysis (destruction of blood
      cells) in pre-disposed individuals, such as those with G6PD deficiency. G6PD deficiency is
      most prevalent in malaria-endemic areas. Therefore, it is essential that data on primaquine's
      safety is available in such areas.

      The investigators hypothesise that lower doses of primaquine have a lower risk of adverse
      effects compared to the WHO-recommended dose, but retain the transmission-blocking efficacy.

      The investigators propose to test this hypothesis in a four-arm clinical trial with a
      non-inferiority design to evaluate the efficacy and a superiority design to evaluate the
      safety of the WHO dose (0.75mg/kg) and lower doses of primaquine for clearance of P.
      falciparum gametocytes in children in Uganda. The study will include a pharmacokinetic
      analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean number of days to gametocyte clearance (gametocyte clearance time, GCT)</measure>
    <time_frame>14 days</time_frame>
    <description>Mean number of days per treatment arm for gametocytes to become undetectable using sub-microscopic molecular testing methods (real-time nucleic acid sequence-based amplification, QT-NASBA)and interpolated from measured data points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean (+/- SD) maximal fall in Hb (g/dL) from enrollment to day 28 of follow-up</measure>
    <time_frame>28 days</time_frame>
    <description>Mean maximal greatest negative difference in Hb (measured by Hemocue®) from enrollment value per treatment arm over 28 days follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean (+/- SD) area under the curve of gametocyte density per day during 14 days of follow-up</measure>
    <time_frame>14 days</time_frame>
    <description>An estimate of the area under the curve of gametocytes (measured by QT-NASBA) seen over time, averaged per day of follow up (days 0-14) and interpolated from measured data points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement for blood transfusion</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of children receiving blood transfusion per treatment arm during days 0-28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up day of Hb nadir</measure>
    <time_frame>28 days</time_frame>
    <description>Mean day of follow up (day 0-28) per treatment arm of lowest Hb measurement (by Hemocue®)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events by sign, symptom, laboratory parameter and relationship to taking study drug</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage (number) per treatment arm during days 0-28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of gastrointestinal symptoms after taking study drug</measure>
    <time_frame>6 days</time_frame>
    <description>Percentage (number) of children with gastrointestinal symptoms per treatment arm during days 2-7</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">468</enrollment>
  <condition>Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Non-active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose primaquine (PQ1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lowest experimental dose of primaquine base: 0.1mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate dose primaquine (PQ2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate experimental dose of primaquine base: 0.4mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference dose primaquine (PQ-R)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>WHO-recommended dose of primaquine base: 0.75mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine</intervention_name>
    <description>Single dose of oral primaquine phosphate. Comparator dose is 0.75mg/kg primaquine base. Each experimental arm is a different (reduced) dose of primaquine phosphate. Placebo contains no primaquine phosphate (non-active ingredients only).</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Low dose primaquine (PQ1)</arm_group_label>
    <arm_group_label>Intermediate dose primaquine (PQ2)</arm_group_label>
    <arm_group_label>Reference dose primaquine (PQ-R)</arm_group_label>
    <other_name>primaquine phosphate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;/= 1 year and &lt;/= 10 years

          -  Weight over 10kg

          -  Fever &gt;38 degrees C (tympanic) or history of fever in the last 24 hours

          -  P. falciparum parasitaemia &lt;500 000/µl

          -  Normal G6PD enzyme function

        Exclusion Criteria:

          -  Enrolled in another study

          -  Evidence of severe illness/ danger signs

          -  Known allergy to study medications

          -  Haemoglobin &lt; 8g/dL)

          -  Started menstruation

          -  Pregnancy or breastfeeding

          -  Primaquine taken within the last 4 weeks

          -  Blood transfusion within the last 90 days

          -  Non-falciparum malaria co-infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice C Eziefula, MBBS MCRP MRCPath</last_name>
    <role>Principal Investigator</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walukuba Health Centre IV</name>
      <address>
        <city>Jinja</city>
        <state>Eastern Region</state>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <reference>
    <citation>Bousema T, Okell L, Shekalaghe S, Griffin JT, Omar S, Sawa P, Sutherland C, Sauerwein R, Ghani AC, Drakeley C. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malar J. 2010 May 24;9:136. doi: 10.1186/1475-2875-9-136.</citation>
    <PMID>20497536</PMID>
  </reference>
  <reference>
    <citation>Shekalaghe S, Drakeley C, Gosling R, Ndaro A, van Meegeren M, Enevold A, Alifrangis M, Mosha F, Sauerwein R, Bousema T. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS One. 2007 Oct 10;2(10):e1023.</citation>
    <PMID>17925871</PMID>
  </reference>
  <reference>
    <citation>Schneider P, Bousema JT, Gouagna LC, Otieno S, van de Vegte-Bolmer M, Omar SA, Sauerwein RW. Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito infection. Am J Trop Med Hyg. 2007 Mar;76(3):470-4.</citation>
    <PMID>17360869</PMID>
  </reference>
  <reference>
    <citation>Shekalaghe SA, ter Braak R, Daou M, Kavishe R, van den Bijllaardt W, van den Bosch S, Koenderink JB, Luty AJ, Whitty CJ, Drakeley C, Sauerwein RW, Bousema T. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrob Agents Chemother. 2010 May;54(5):1762-8. doi: 10.1128/AAC.01135-09. Epub 2010 Mar 1.</citation>
    <PMID>20194698</PMID>
  </reference>
  <reference>
    <citation>Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo AP, Naing AL, Nyo MY, Myint NZ, Imwong M, Ashley E, Lee SJ, White NJ. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis. 2010 Oct;10(10):673-81. doi: 10.1016/S1473-3099(10)70187-0. Epub 2010 Sep 9.</citation>
    <PMID>20832366</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2011</study_first_submitted>
  <study_first_submitted_qc>June 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2011</study_first_posted>
  <last_update_submitted>June 11, 2013</last_update_submitted>
  <last_update_submitted_qc>June 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malaria</keyword>
  <keyword>uncomplicated malaria</keyword>
  <keyword>gametocytocidal drug</keyword>
  <keyword>gametocytocidal</keyword>
  <keyword>gametocyte</keyword>
  <keyword>primaquine</keyword>
  <keyword>transmission blocking</keyword>
  <keyword>malaria transmission</keyword>
  <keyword>sexual parasite</keyword>
  <keyword>sexual stage</keyword>
  <keyword>Uganda</keyword>
  <keyword>Africa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primaquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

